Figure 1.

Increased numbers of Foxp3⁺CD62L⁻CD4⁺ T cells found in infliximab-treated RA patients compared with patients with active disease and healthy controls. (A) Representative FACS plots gated on the CD4⁺ population depicting PBMCs from healthy controls, active RA patients, and infliximab-treated RA patients stained with anti-CD4 and anti-Foxp3. The percentages of Foxp3⁺ cells in the CD4⁺ gate for individual RA patients, before and after infliximab, and healthy controls are shown in the chart. (B) Histograms were gated on CD4⁺CD25^high cells (as indicated), and the expression of CD62L is shown. (C) PBMCs from the same groups as in A were stained with anti-CD4, anti-Foxp3, and anti-CD62L. The histograms indicate the expression of CD62L in the CD4⁺Foxp3⁺ population. Data from individual patients are shown in the chart. (D) CCR7 and CD45RO expression on the CD4⁺Foxp3⁺ T cell population in the different patient groups. (E) CCR7 and CD45RO expression on the CD4⁺FoxP3⁺CD62L⁻ population from an RA patient treated with infliximab. Results are representative of six patients or healthy individuals for each group. The dashed line in the FACS plots represents the isotype control for the specific marker examined.